Compelo Medical Devices - Latest industry news and analysis is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More

FDA approves Bracco MultiHance injection for MRA use

Bracco Diagnostics has obtained the US Food and Drug Administration (FDA) clearance for use of its MultiHance (gadobenate dimeglumine) injection, 529 mg/mL, in magnetic resonance angiography (MRA), designed to evaluate adults with known or suspected renal or aorto-ilio-femoral occlusive vascular disease.

Previously, MultiHance was approved as gadolinium-based contrast agent (GBCA) for intravenous use in magnetic resonance imaging (MRI) of the central nervous system in adults and children over 2 years of age to visualize lesions with abnormal blood brain barrier or abnormal vascularity of the brain, spine and associated tissues.

The company said 0.1 mmol/kg (0.2 mL/kg) of MultiHance is the recommended dose for both MRI and MRA examinations.

The approval of MultiHance in MRA was based on data from two prospective, multi-center trials (one for each arterial vascular territory: renal and aorto-ilio-femoral), designed to asses the safety and efficacy of MultiHance.

The diagnostic efficacy for detecting/excluding clinically significant steno-occlusive disease (= 51% stenosis) was assessed based on comparing sensitivity and specificity between MultiHance MRA and non-contrast MRA, with DSA as the standard.

Results of the trials demonstrated significant increase in both sensitivity and specificity of MultiHance-enhanced MRA over non-contrast MRA in detecting clinically significant steno-occlusive disease.

Bracco Diagnostics medical and regulatory affairs group senior vice president Dr. Alberto Spinazzi said MultiHance has long been distinguished in the MRI of the CNS as a GBCA characterized by a strong increase in relaxivity in any medium containing serum proteins, contributing to increased contrast-to-noise ratio and lesion-to-brain ratio and improved visualization.

"It also counts a strong record of safety that spans over 14 million administered doses," Spinazzi added.